Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Express, NeoGenomics combine in Dx commercialisation pact

This article was originally published in Clinica

Executive Summary

Personalised medicine specialist Gene Express has licensed its standardised reverse transcription polymerase chain reaction (StaRT-PCR) and standardised expression measurement (SEM) centre technology to clinical reference lab NeoGenomics Laboratories. In return, Gene Express will receive help from NeoGenomics to obtain FDA approval for its lung cancer risk prediction and BCR/ABL gene expression tests. The agreements allow NeoGenomics to commercialise the Gene Express tests, validate any future Gene Express technology for FDA requirements and use StaRT-PCR for its own commercial purposes. Gene Express (Wilmington, North Carolina) expects to submit the lung cancer risk prediction test for FDA approval in Q4 2008 and to begin clinical trials for its BCR/ABL test in Q1 2009. Financial details of the agreements were not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel